Skystar Bio-Pharma (SKBI) Tops Q1 EPS by 8c; Reiterates Outlook
Tweet
Share
E-mailGet Alerts SKBI Hot Sheet
Join SI Premium – FREE
Skystar Bio-Pharmaceutical Company (NASDAQ: SKBI) reported Q1 EPS of $0.27, $0.08 better than the analyst estimate of $0.19. Revenue for the quarter came in at $7.09 million versus the consensus estimate of $6.71 million.
Reiterates outlook.
Reiterates outlook.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- SYNNEX Corp. (SNX) Tops Q3 EPS by $1.04, Beats on Revenue; Offers Q4 Guidance
- Scholastic Corp (SCHL) Misses Q1 EPS by 23c
- Cintas Corp. (CTAS) Tops Q1 EPS by 1c, Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
